Malaria

What is Malaria?

Malaria is a life-threatening infectious disease caused by parasites that are transmitted through the bites of infected female Anopheles mosquitoes. The disease primarily affects people in tropical and subtropical regions, with sub-Saharan Africa bearing the highest burden. According to the World Health Organization, malaria infected an estimated 249 million people worldwide in 2022, making it one of the most significant global health challenges. While preventable and treatable when diagnosed early, malaria continues to cause hundreds of thousands of deaths annually, particularly among young children and pregnant women in endemic areas.

Key statistics

Global cases (2022)	249 million cases worldwide
Annual deaths	Approximately 608,000 deaths in 2022
Most affected population	Children under 5 years account for 76% of deaths
Geographic distribution	95% of cases occur in sub-Saharan Africa

Symptoms

Common early symptoms: Fever, chills, headache, muscle aches, fatigue, nausea, vomiting, sweating.

The classic presentation of malaria includes cyclical fever episodes that occur every 48-72 hours, depending on the parasite species. Early symptoms typically appear 7-30 days after being bitten by an infected mosquito and can be easily mistaken for flu-like illness. Patients often experience intense chills followed by high fever and profuse sweating as the fever breaks.

Progressive symptoms may include severe headache, abdominal pain, diarrhea, anemia, and jaundice. In severe cases, particularly with Plasmodium falciparum infection, patients can develop cerebral malaria with confusion, seizures, and altered consciousness.

Severe complications include respiratory distress, kidney failure, severe anemia, hypoglycemia, and multi-organ failure. These symptoms require immediate medical intervention as they can rapidly progress to death without proper treatment.

Causes and risk factors

Malaria is caused by five species of Plasmodium parasites: P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi. The parasites are transmitted exclusively through bites from infected female Anopheles mosquitoes, which typically bite between dusk and dawn.

Primary risk factors include: Living in or traveling to endemic areas, particularly sub-Saharan Africa, parts of Asia, Central and South America, and certain Pacific islands. Children under 5 years, pregnant women, and people with compromised immune systems face higher risk of severe disease.

Environmental factors that increase transmission risk include proximity to stagnant water where mosquitoes breed, inadequate housing that allows mosquito entry, and seasonal patterns during rainy seasons when mosquito populations peak.

Individual susceptibility varies, with people of African descent having some natural protection against P. vivax due to genetic factors, while those with sickle cell trait have partial protection against severe P. falciparum malaria.

Prevention

Prevention strategies focus on avoiding mosquito bites and, in some cases, taking preventive medications. The most effective approach combines multiple protective measures.

Vector control measures include sleeping under insecticide-treated bed nets, using indoor residual spraying in homes, and eliminating mosquito breeding sites by removing stagnant water sources.

Personal protection involves wearing long-sleeved clothing and long pants during evening hours, using insect repellents containing DEET, picaridin, or oil of lemon eucalyptus, and staying in air-conditioned or well-screened areas when possible.

Chemoprophylaxis may be recommended for travelers to endemic areas, with specific medications chosen based on destination, duration of travel, and local resistance patterns. Common prophylactic medications include atovaquone-proguanil, doxycycline, and mefloquine.

Vaccination options include the RTS,S/AS01 vaccine (Mosquirix), recommended by WHO for children in high-risk areas, though it provides only partial protection and must be combined with other preventive measures.

Complications

Without prompt treatment, malaria can rapidly progress to severe, life-threatening complications. Cerebral malaria, primarily caused by P. falciparum, can lead to coma, permanent neurological damage, and death within 24-48 hours.

Organ-specific complications include acute kidney injury, pulmonary edema, severe anemia requiring blood transfusion, and liver dysfunction. Pregnant women may experience miscarriage, premature delivery, low birth weight, and maternal death.

Metabolic complications such as hypoglycemia and acidosis can develop rapidly, particularly in children and pregnant women. Repeated malaria infections can lead to chronic anemia, impaired cognitive development in children, and increased susceptibility to other infections.

Long-term consequences may include post-malaria neurological syndrome, chronic fatigue, and in areas with P. vivax or P. ovale, relapsing infections months or years after initial treatment due to dormant liver stages.

Diagnosis

Rapid and accurate diagnosis is crucial for effective malaria management. The gold standard remains microscopic examination of thick and thin blood smears, which can identify parasite species and quantify parasitemia levels.

Rapid diagnostic tests (RDTs) detect malaria antigens in blood and provide results within 15-20 minutes, making them valuable in resource-limited settings. These tests are particularly useful for detecting P. falciparum and P. vivax.

Molecular techniques such as polymerase chain reaction (PCR) offer the highest sensitivity and specificity but require specialized laboratory facilities. PCR is particularly useful for detecting low-level parasitemia and mixed infections.

Clinical diagnosis should consider travel history, symptom onset timing, and epidemiological factors. Healthcare providers should maintain high clinical suspicion in anyone presenting with fever who has been in endemic areas within the past year.

Treatment

Treatment depends on the Plasmodium species, severity of infection, and local resistance patterns. Artemisinin-based combination therapies (ACTs) are the first-line treatment for uncomplicated P. falciparum malaria.

Uncomplicated malaria treatment typically involves oral medications such as artemether-lumefantrine, artesunate-amodiaquine, or dihydroartemisinin-piperaquine for P. falciparum infections.

Severe malaria requires immediate hospitalization and intravenous artesunate, which has largely replaced quinine as the standard of care due to superior efficacy and fewer side effects.

Species-specific treatment for P. vivax and P. ovale includes chloroquine for the blood stage, followed by primaquine or tafenoquine to eliminate dormant liver stages and prevent relapses.

Supportive care may include management of fever, fluid balance, blood transfusion for severe anemia, and treatment of complications such as seizures or respiratory distress.

Prognosis

With prompt diagnosis and appropriate treatment, the prognosis for uncomplicated malaria is excellent, with cure rates exceeding 95%. Most patients experience rapid improvement within 48-72 hours of starting treatment, with complete recovery within one week.

Severe malaria outcomes depend on early recognition and treatment. Even with optimal care, severe malaria carries a mortality rate of 10-20% in adults and up to 15% in children, emphasizing the importance of prevention and early treatment.

Long-term prognosis is generally good for survivors of severe malaria, though some may experience persistent neurological effects, particularly children who survived cerebral malaria. Cognitive impairment and behavioral changes may persist in some cases.

Recurrent infections are common in endemic areas, but repeated exposure typically leads to partial immunity that reduces severity over time, though complete immunity is rarely achieved.

Quality of life

Living in malaria-endemic areas requires ongoing vigilance and preventive measures. Families should maintain consistent use of bed nets, ensure prompt medical care for fevers, and participate in community vector control efforts.

Daily prevention practices include keeping living areas clean and free of stagnant water, using appropriate clothing during high-risk hours, and maintaining bed nets in good condition. Indoor plants should be avoided near sleeping areas as they can harbor mosquitoes.

Travel considerations for people from endemic areas visiting malaria-free regions should include awareness that partial immunity may wane over time, increasing risk upon return. Travelers to endemic areas should begin prophylaxis before departure and continue as recommended after return.

Psychological support may be beneficial for families dealing with recurrent infections or those who have experienced severe malaria, as the fear of recurrence can significantly impact quality of life and sleep patterns.

Pregnancy and fertility

Malaria during pregnancy poses significant risks to both mother and fetus, including maternal anemia, miscarriage, premature delivery, low birth weight, and maternal death. Pregnant women have reduced immunity to malaria and may experience more severe infections.

Preventive measures during pregnancy include sleeping under insecticide-treated nets and, in high-transmission areas, intermittent preventive treatment with sulfadoxine-pyrimethamine starting in the second trimester.

Treatment considerations during pregnancy require careful drug selection. Artesunate is safe in the second and third trimesters, while quinine may be used in the first trimester for severe malaria.

Postpartum care should include continued protection measures as immunity remains reduced for several months after delivery. Breastfeeding is safe and encouraged, even during maternal malaria treatment.

Children

Children under 5 years are at highest risk for severe malaria and death, as they have not yet developed partial immunity. Symptoms may be atypical, including poor feeding, excessive crying, drowsiness, or difficulty breathing.

Pediatric treatment requires weight-based dosing of antimalarial medications, with liquid formulations often preferred for young children. Artesunate suppositories may be used for severe malaria when intravenous access is difficult.

Developmental considerations include monitoring for cognitive effects following severe malaria episodes, particularly cerebral malaria. Some children may require educational support or physical therapy following recovery.

Vaccination schedules in endemic areas should include the RTS,S malaria vaccine where recommended, typically given in a 4-dose schedule starting at 5 months of age.

When to see a doctor

Immediate medical attention is required for: Any fever in someone who has been in a malaria-endemic area within the past year, particularly within 3 months. Symptoms such as severe headache, confusion, difficulty breathing, persistent vomiting, or signs of severe illness warrant emergency evaluation.

Urgent care is needed for: High fever (above 38.5°C/101.3°F), chills, body aches, or fatigue developing after travel to endemic areas. Children, pregnant women, and immunocompromised individuals should seek care immediately for any concerning symptoms.

Routine follow-up should be arranged for completion of treatment courses and to ensure complete parasite clearance, particularly for P. vivax and P. ovale infections requiring liver-stage treatment.

Regional context

The Caucasus region, including Georgia, Armenia, and Azerbaijan, is considered malaria-free, with elimination achieved through successful control programs in the mid-20th century. However, imported cases may occur in travelers returning from endemic areas.

Regional surveillance maintains vigilance for imported cases and potential reintroduction, with healthcare systems trained to recognize and manage malaria despite its rarity. Cross-border collaboration helps maintain elimination status.

Travel medicine services in the region provide pre-travel consultation and prophylaxis for residents traveling to endemic areas, with post-travel monitoring for imported cases.

Research and clinical trials

Current research focuses on developing new antimalarial drugs to combat resistance, improving diagnostic tools for field use, and advancing next-generation vaccines with higher efficacy than current options.

Vaccine development includes trials of R21/Matrix-M, which showed promising efficacy results, and research into transmission-blocking vaccines that could prevent mosquito infection.

Drug development targets novel mechanisms of action to overcome artemisinin resistance, with several compounds in clinical trials. Tafenoquine represents a recent advancement for P. vivax radical cure.

Vector control research explores genetically modified mosquitoes, new insecticides, and improved bed net technologies. Patients interested in participating in research can find studies at ClinicalTrials.gov.

Frequently asked questions

Can malaria be completely eliminated from the body?

Yes, with appropriate treatment, malaria can be completely cured. However, P. vivax and P. ovale require specific medications like primaquine to eliminate dormant liver stages and prevent relapses.

How long does it take to develop symptoms after a mosquito bite?

Symptoms typically appear 7-30 days after being bitten by an infected mosquito, though this can vary by parasite species. P. vivax can cause symptoms months or even years later due to dormant liver stages.

Is malaria contagious between people?

Malaria is not contagious through casual contact. It can only be transmitted through mosquito bites, blood transfusions, organ transplants, or from mother to child during pregnancy or delivery.

Do antimalarial drugs have side effects?

Yes, antimalarial medications can cause side effects ranging from mild nausea to more serious reactions. Your healthcare provider will select the most appropriate medication based on your destination, medical history, and risk factors.

Can you get malaria more than once?

Yes, people can get malaria multiple times. While repeated infections may provide some partial immunity that reduces severity, complete protection is rarely achieved, and prevention measures remain important.

Support and resources

World Health Organization (WHO) – Comprehensive malaria information and global elimination efforts: https://www.who.int/health-topics/malaria

Malaria No More – Global nonprofit working to end malaria deaths: https://www.malarianomore.org

Roll Back Malaria Partnership – Global platform for coordinated action against malaria: https://rollbackmalaria.org

Centers for Disease Control and Prevention (CDC) – Malaria prevention and treatment guidelines: https://www.cdc.gov/malaria

Medicines for Malaria Venture (MMV) – Drug development partnership: https://www.mmv.org

Related conditions

Dengue fever – Another mosquito-borne disease with similar fever presentation but caused by dengue virus rather than parasites.

Typhoid fever – Bacterial infection that can present with similar symptoms and commonly affects travelers to tropical regions.

Cite this page

GMJ News Desk. “Malaria.” GMJ News — Georgian Medical Journal, 1 June 2026. https://news.gmj.ge/condition/malaria/

Copy citation

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.